[HTML][HTML] Glycogen synthase kinase-3α promotes fatty acid uptake and lipotoxic cardiomyopathy

M Nakamura, T Liu, S Husain, P Zhai, JS Warren…�- Cell metabolism, 2019 - cell.com
M Nakamura, T Liu, S Husain, P Zhai, JS Warren, CP Hsu, T Matsuda, CJ Phiel, JE Cox
Cell metabolism, 2019cell.com
Obesity induces lipotoxic cardiomyopathy, a condition in which lipid accumulation in
cardiomyocytes causes cardiac dysfunction. Here, we show that glycogen synthase kinase-
3α (GSK-3α) mediates lipid accumulation in the heart. Fatty acids (FAs) upregulate GSK-3α,
which phosphorylates PPARα at Ser280 in the ligand-binding domain (LBD). This
modification ligand independently enhances transcription of a subset of PPARα targets,
selectively stimulating FA uptake and storage, but not oxidation, thereby promoting lipid�…
Summary
Obesity induces lipotoxic cardiomyopathy, a condition in which lipid accumulation in cardiomyocytes causes cardiac dysfunction. Here, we show that glycogen synthase kinase-3α (GSK-3α) mediates lipid accumulation in the heart. Fatty acids (FAs) upregulate GSK-3α, which phosphorylates PPARα at Ser280 in the ligand-binding domain (LBD). This modification ligand independently enhances transcription of a subset of PPARα targets, selectively stimulating FA uptake and storage, but not oxidation, thereby promoting lipid accumulation. Constitutively active GSK-3α, but not GSK-3β, was sufficient to drive PPARα signaling, while cardiac-specific knockdown of GSK-3α, but not GSK-3β, or replacement of�PPARα Ser280 with Ala conferred resistance to lipotoxicity in the heart. Fibrates, PPARα ligands, inhibited phosphorylation of PPARα at Ser280 by inhibiting the interaction of GSK-3α with the LBD of PPARα, thereby reversing lipotoxic cardiomyopathy. These results suggest that GSK-3α promotes lipid anabolism through PPARα-Ser280 phosphorylation, which underlies the development of lipotoxic cardiomyopathy in the context of obesity.
cell.com